Searched for
API SUPPLIERS INDIA
Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugsAnupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharma...- Indian SME pharma firms see shift of orders from China; cost, quality concerns remainSmall and mid-sized Indian pharmaceutical firms are witnessing a shift in orders away from China. As Western buyers diversify their supply ...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhat is needed in the markets these days is realism. Not fear or gloom, but a clear-eyed acceptance of where things actually stand. Realism...
- M1xchange goes live with CGTMSE guarantee cover for MSME receivables financingDigital integration enables financiers to assess eligibility, obtain guarantee cover and complete the guarantee process on the TReDS platfo...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsAs an investor, what you need to do at this point of time is this: A bit of extra work in terms of stock-picking so that you avoid anxiety ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos may rally over 21%, according to analystsWith the US market shedding weight overnight, the probability is high that Thursday will see another day of choppy trading. The best way to...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Geopolitical shocks are forcing companies to rethink procurement intelligence: Claight CEOGeopolitical tensions, tariff uncertainty and repeated supply-chain disruptions are pushing global companies to move from periodic procurem...
- Chasing dues could get easier for small businesses under new rules, MSME Secy Bharat Khera explainsThe number of enterprises in the formal ecosystem has increased from around 16.5 million three to four years ago to 92 million currently, s...
- The Economic Times Startup Awards 2026: Nominees for Startup of the Year and Midas TouchHappy Friday! We are excited to bring to you the 12th edition of The Economic Times Startup Awards (ETSA). A few days before our esteemed j...
- Shiprocket lifts off: The fire that fuels the new logistics engineShiprocket’s strong stock market debut reflects surging investor confidence in India’s tech-driven e-commerce infrastructure. As rapid D2C ...
- Chemical sector: Although long, there is a way around China trouble; combine 20 stocks to get your portfolio’s chemistry rightFor the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- A decade of inclusion: How GeM is transforming public procurement for women entrepreneurs in IndiaGeM's Womaniya initiative has empowered over 200,000 women entrepreneurs in public procurement. This program has dismantled barriers, enabl...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiryIndian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...
- India may allow Remdesivir exporters to sell drug in domestic marketThe measure is expected to boost availability of the drug that’s being used for Covid treatment. Supplies of the drug have been running low...
- Saurabh Mukherjea reveals his 3 favourite pharma stocksOver a two-three-year period, the pricing power in API space will ebb away and margins will come back down, says Saurabh Mukherjea.
- India must manufacture more APIs locally, depend less on China: ExpertsIndia, the world’s third-largest drug producer by volumes, imports 70% of its APIs from China. For some APIs, especially antibiotics, depen...
Load More
